Welcome to the

Karantanos Lab

About Us

The focus of the Karantanos lab is the elucidation of the role of inflammatory signaling in the progression of high-risk myeloid neoplasms and the development of novel targeted therapies to improve the outcomes of patients with these diseases. Specifically, we investigate the regulation and functional implication of JAK2/STAT1 signaling in TP53-mutated myeloid neoplasms by incorporating single cell analysis, CRISPR-Cas9 screens, and signal transduction studies. We also develop antibody-based therapies that target inflammatory mediators in TP53-mutated myelodysplastic syndrome/acute myeloid leukemia (MDS/AML) utilizing xenografts and transgenic mouse models. Finally, we study the effect of RAS inhibition in high-risk MDS and chronic myelomonocytic leukemia.

 

Our Research

Our studies focus on understanding the mechanisms associated with the upregulation of inflammatory signaling in TP53-mutated MDS/AML and its functional implication in disease progression. Particularly, we are interested in the dissection of regulation of IFN-γ signaling and the implication of STAT1 in TP53-mutated leukemogenesis and treatment resistance. We also develop antibody-drug conjugates and bi-specific antibodies targeting chemokine receptors and study the efficacy of combinational therapeutic approaches for TP53-mutated MDS/AML. We finally, investigate the activity of RAS inhibitors in RAS mutated chronic myeloid neoplasms and secondary acute myeloid leukemia arising from them. 

Our work incorporates signal transduction studies, CRISPR-Cas9 gene editing via viral transduction and electroporation, CRISPR-Cas9 screens, single cell transcriptomic analysis, cell line and patient-derived xenograft models and transgenic mice.

 

News & Updates

Let's Work Together!

The Karantanos Lab is interested in collaborating. Drop us a line.